Castle Biosciences CEO, trusts sell 6,942 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Castle Biosciences (CSTL) President and Chief Executive Officer Derek J. Maetzold and two trusts reported sales totaling 6,942 shares of common stock on November 16, 2026, at a weighted-average sale price of $32.92 per share. Maetzold sold 3,904 shares directly; The Maetzold Descendants 2020 Trust sold 1,642 and Derek Maetzold 2020 Irrevocable Trust sold 1,396. Each of the three reported positions was zero after its sale. The transactions were made under a Rule 10b5-1 plan adopted June 2, 2026, in multiple trades priced from $32.62 to $33.39.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 3,904 | $32.92 | $129K |
| Sale | Common Stock F1, F2, F3 | 1,642 | $32.92 | $54K |
| Sale | Common Stock F1, F2, F4 | 1,396 | $32.92 | $46K |
| Holding | Common Stock F5 | -- | -- | -- |
| Holding | Common Stock F6 | -- | -- | -- |
| Holding | Common Stock F7 | -- | -- | -- |
| Holding | Common Stock F8 | -- | -- | -- |
| Holding | Common Stock F9 | -- | -- | -- |
| Holding | Common Stock F10 | -- | -- | -- |
| Holding | Common Stock F11 | -- | -- | -- |
| Holding | Common Stock F12 | -- | -- | -- |
Footnotes (12)
- F1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
- F2. This transaction was executed in multiple trades at prices ranging from $32.62 to $33.39, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.
- F4. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.
- F5. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.
- F6. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F7. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F8. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.
- F9. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.
- F10. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
- F11. Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.
- F12. Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.
Key Figures
Key Terms
Rule 10b5-1 plan financial
weighted-average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.